| 1 |
Patel AH, Peddu D, Amin S, Elsaid MI, Minacapelli CD, Chandler TM, Catalano C, Rustgi VK. Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. J Clin Transl Hepatol 2023;11:502-15. [PMID: 36643037 DOI: 10.14218/JCTH.2022.00204] [Reference Citation Analysis]
|
| 2 |
Zhang S, Mak LY, Yuen MF, Seto WK. Screening strategy for non-alcoholic fatty liver disease. Clin Mol Hepatol 2023;29:S103-22. [PMID: 36447420 DOI: 10.3350/cmh.2022.0336] [Reference Citation Analysis]
|
| 3 |
Shi MY, Wong C, Lee TP. Effect modification of hepatitis B viral load on the association between metabolic risk factors and hepatic steatosis. Transl Gastroenterol Hepatol 2023;8:6. [PMID: 36704648 DOI: 10.21037/tgh-22-44] [Reference Citation Analysis]
|
| 4 |
Nam H, Yoo JJ, Cho Y, Kang SH, Ahn SB, Lee HW, Jun DW, Song DS, Choi M. Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis. Dig Liver Dis 2023:S1590-8658(22)00861-1. [PMID: 36653265 DOI: 10.1016/j.dld.2022.12.013] [Reference Citation Analysis]
|
| 5 |
Fialho A, Fialho A, Ribeiro B, Malespin M, De Melo S, Schey R, Ghali P. Association Between Helicobacter pylori and Steatosis Severity on Transient Elastography. Cureus 2023;15:e34042. [PMID: 36699110 DOI: 10.7759/cureus.34042] [Reference Citation Analysis]
|
| 6 |
Elhini SH, Wahsh EA, Elberry AA, El Ameen NF, Abdelfadil Saedii A, Refaie SM, Elsayed AA, Rabea HM. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals (Basel) 2022;15. [PMID: 36558967 DOI: 10.3390/ph15121516] [Reference Citation Analysis]
|
| 7 |
Oses M, Medrano M, Margareto Sanchez J, Portillo MP, Aguilera CM, Altmäe S, Labayen I. Peripheral blood mononuclear cells-expressed miRNA profiles derived from children with metabolic-associated fatty liver disease and insulin resistance. Pediatr Obes 2022;17:e12966. [PMID: 36054529 DOI: 10.1111/ijpo.12966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Li L, Hou K, Yuan M, Zhang Y, Zhang Y. Change lifestyle modification plan/transtheoretical model in non-alcoholic simple fatty liver disease: a pilot randomized study. BMC Gastroenterol 2022;22:483. [PMID: 36424552 DOI: 10.1186/s12876-022-02506-4] [Reference Citation Analysis]
|
| 9 |
Guo L, Jiang W, Quan L, Teng X, Zhao J, Qiu H. Mechanism of PDZK1 in Hepatocellular Carcinoma Complicated with Hyperuricemia. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/1403454] [Reference Citation Analysis]
|
| 10 |
Yadav M, Chauhan NS. Role of gut-microbiota in disease severity and clinical outcomes. Briefings in Functional Genomics 2022. [DOI: 10.1093/bfgp/elac037] [Reference Citation Analysis]
|
| 11 |
Abedin N, Tannapfel A, Wild PJ, Tischoff I. Histopathologische Evaluierung der nichtalkoholischen Fettleber. Wien klin Mag 2022;25:146-154. [DOI: 10.1007/s00740-022-00444-1] [Reference Citation Analysis]
|
| 12 |
Al Mahtab M, Ghosh J, Bhatia S, Nagral A, Bangar M, Menezes S, Butt N, Manchanayake JH, Singh SP. Gender Differences in Nonalcoholic Fatty Liver Disease. Euroasian Journal of Hepato-Gastroenterology 2022;12:S19-S25. [DOI: 10.5005/jp-journals-10018-1370] [Reference Citation Analysis]
|
| 13 |
Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen A. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00165-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Wang Z, Zhao H, Zhou Q, Teekaraman Y. Analysis of Risk Factors of Coronary Heart Disease and Its Correlation with Inflammatory Factors in Patients with Type 2 Diabetes Mellitus. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/6818888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med 2022;14:eabk0855. [PMID: 35675435 DOI: 10.1126/scitranslmed.abk0855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 16 |
Fu L, Zhang W, Ao Y, Zheng Z, Hu H. Efficacy of aerobic and resistance exercises in improving visceral adipose in patients with non-alcoholic fatty liver: a meta-analysis of randomized controlled trials. Z Gastroenterol. [DOI: 10.1055/a-1742-4257] [Reference Citation Analysis]
|
| 17 |
Ames JB, Djerboua M, Terrault NA, Booth CM, Flemming JA. Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. Can J Gastroenterol Hepatol 2022;2022:6175913. [PMID: 35308801 DOI: 10.1155/2022/6175913] [Reference Citation Analysis]
|
| 18 |
Bashir A, Duseja A, De A, Mehta M, Tiwari P. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Seo DH, Cho Y, Seo S, Ahn SH, Hong S, Ha KH, Shim JS, Kim HC, Kim DJ, Kim SH. Association between Metabolically Healthy Obesity and Subclinical Atherosclerosis in the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) Cohort. J Clin Med 2022;11. [PMID: 35566567 DOI: 10.3390/jcm11092440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Aneni EC, Saeed GJ, Bittencourt MS, Cainzos-achirica M, Osondu CU, Budoff M, Parise ER, Santos RD, Nasir K. Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals. PLoS ONE 2022;17:e0266505. [DOI: 10.1371/journal.pone.0266505] [Reference Citation Analysis]
|
| 21 |
Serdarova M, Dimova R, Chakarova N, Grozeva G, Todorova A, Tsarkova P, Marinova C, Popov D, Mateva L, Tankova T. Metabolic determinants of NAFLD in adults with type 1 diabetes. Diabetes Research and Clinical Practice 2022;186:109819. [DOI: 10.1016/j.diabres.2022.109819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 23 |
Abedin N, Tannapfel A, Wild PJ, Tischoff I. Histopathologische Evaluierung der nichtalkoholischen Fettleber. Pathologe 2022;43:157-166. [DOI: 10.1007/s00292-022-01052-w] [Reference Citation Analysis]
|
| 24 |
Arora M, Kutinová Canová N, Farghali H. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Toda-Oti KS, Stefano JT, Cavaleiro AM, Carrilho FJ, Correa-Gianella ML, Oliveira CPMS. Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. Metab Syndr Relat Disord 2022. [PMID: 35020496 DOI: 10.1089/met.2020.0104] [Reference Citation Analysis]
|
| 26 |
Ebrahimi R, Pasalar P, Shokri H, Shabani M, Emamgholipour S. Evidence for the effect of soluble uric acid in augmenting endoplasmic reticulum stress markers in human peripheral blood mononuclear cells. J Physiol Biochem 2022. [PMID: 34985729 DOI: 10.1007/s13105-021-00869-y] [Reference Citation Analysis]
|
| 27 |
Mahajan VK, Chauhan NS, Rana BS, Mehta KS, Hooda S, Chauhan PS, Kukreja A. The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study. J Clin Exp Hepatol 2022;12:785-92. [PMID: 35677516 DOI: 10.1016/j.jceh.2021.11.016] [Reference Citation Analysis]
|
| 28 |
Kuang L, Zhou W, Jiang Y. Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis. PLoS One 2021;16:e0260479. [PMID: 34855819 DOI: 10.1371/journal.pone.0260479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 29 |
Lu Y, Hu L, Song J, Wan J, Chen H, Yin J. Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study. BMC Endocr Disord 2021;21:231. [PMID: 34794397 DOI: 10.1186/s12902-021-00899-z] [Reference Citation Analysis]
|
| 30 |
Stine JG, Soriano C, Schreibman I, Rivas G, Hummer B, Yoo E, Schmitz K, Sciamanna C. Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3604-11. [PMID: 33098023 DOI: 10.1007/s10620-020-06673-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 31 |
Zhang Y, Li JX, Zhang Y, Wang YL. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis . World J Clin Cases 2021; 9(23): 6654-6662 [PMID: 34447812 DOI: 10.12998/wjcc.v9.i23.6654] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 32 |
Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 33 |
Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, Johnson RJ, Jensen T. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22:351-66. [PMID: 33389543 DOI: 10.1007/s11154-020-09621-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 34 |
Sheng G, Xie Q, Wang R, Hu C, Zhong M, Zou Y. Waist-to-height ratio and non-alcoholic fatty liver disease in adults. BMC Gastroenterol 2021;21:239. [PMID: 34034671 DOI: 10.1186/s12876-021-01824-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 35 |
Arumugam MK, Paal MC, Donohue TM Jr, Ganesan M, Osna NA, Kharbanda KK. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel) 2021;10. [PMID: 34067313 DOI: 10.3390/biology10060456] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 36 |
Li L, Yang L, Yang F, Zhao XL, Xue S, Gong FH. Ginkgo biloba Extract 50 (GBE50) Ameliorates Insulin Resistance, Hepatic Steatosis and Liver Injury in High Fat Diet-Fed Mice. J Inflamm Res 2021;14:1959-71. [PMID: 34040411 DOI: 10.2147/JIR.S302934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 37 |
Gor R, Siddiqui NA, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Malik M, Hamid P. Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand. Cureus 2021;13:e14858. [PMID: 34104598 DOI: 10.7759/cureus.14858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 38 |
Zhang Y, Li K, Kong A, Zhou Y, Chen D, Gu J, Shi H. Dysregulation of autophagy acts as a pathogenic mechanism of non-alcoholic fatty liver disease (NAFLD) induced by common environmental pollutants. Ecotoxicol Environ Saf 2021;217:112256. [PMID: 33901779 DOI: 10.1016/j.ecoenv.2021.112256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 39 |
Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol 2021;19:580-589.e5. [PMID: 32531342 DOI: 10.1016/j.cgh.2020.05.064] [Cited by in Crossref: 148] [Cited by in F6Publishing: 147] [Article Influence: 74.0] [Reference Citation Analysis]
|
| 40 |
Moura Cunha G, Navin PJ, Fowler KJ, Venkatesh SK, Ehman RL, Sirlin CB. Quantitative magnetic resonance imaging for chronic liver disease. Br J Radiol 2021;94:20201377. [PMID: 33635729 DOI: 10.1259/bjr.20201377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 41 |
Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants (Basel) 2021;10:270. [PMID: 33578702 DOI: 10.3390/antiox10020270] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 27.5] [Reference Citation Analysis]
|
| 42 |
Esteve-Luque V, Padró-Miquel A, Fanlo-Maresma M, Corbella E, Corbella X, Pintó X, Candás-Estébanez B. Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia. Nutrients 2021;13:552. [PMID: 33567543 DOI: 10.3390/nu13020552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 44 |
Caturano A, Acierno C, Nevola R, Pafundi PC, Galiero R, Rinaldi L, Salvatore T, Adinolfi LE, Sasso FC. Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. Processes 2021;9:135. [DOI: 10.3390/pr9010135] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 45 |
Elaziz Ewida AA, Dala A, Ezz EA. The relationship between nonalcoholic fatty liver disease and cancers. Menoufia Med J 2021;34:409. [DOI: 10.4103/mmj.mmj_312_19] [Reference Citation Analysis]
|
| 46 |
Sonmez A, Ercin CN, Cesur M, Dogru T. Nutraceuticals for Non-alcoholic Fatty Liver Disease. Nutraceuticals and Cardiovascular Disease 2021. [DOI: 10.1007/978-3-030-62632-7_9] [Reference Citation Analysis]
|
| 47 |
Mamedov M, Karimov A. Secondary hyperlipidemia: features of manifestation in various somatic diseases. Profil med 2021;24:105. [DOI: 10.17116/profmed202124031105] [Reference Citation Analysis]
|
| 48 |
Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:1-13. [PMID: 33747521 DOI: 10.1093/gastro/goaa066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 49 |
Morandi A, Di Sessa A, Zusi C, Umano GR, El Mazloum D, Fornari E, Miraglia Del Giudice E, Targher G, Maffeis C. Nonalcoholic Fatty Liver Disease and Estimated Insulin Resistance in Obese Youth: A Mendelian Randomization Analysis. J Clin Endocrinol Metab 2020;105:dgaa583. [PMID: 32841326 DOI: 10.1210/clinem/dgaa583] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 50 |
Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. J Clin Transl Hepatol 2020;8:347-53. [PMID: 33083258 DOI: 10.14218/JCTH.2020.00027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 51 |
Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 52 |
Hsu CL, Wu FZ, Lin KH, Chen YH, Wu PC, Chen YH, Chen CS, Wang WH, Mar GY, Yu HC. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. Clin Transl Gastroenterol. 2019;10:1-8. [PMID: 31082856 DOI: 10.14309/ctg.0000000000000042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 53 |
Eshraghian A, Nikeghbalian S, Geramizadeh B, Kazemi K, Shamsaeefar A, Malek-Hosseini SA. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. Clin Res Hepatol Gastroenterol 2020;44:572-8. [PMID: 31611031 DOI: 10.1016/j.clinre.2019.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 54 |
Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 55 |
Movahedian M, Rahmani J, Hashemi Nazari SS, Mohamadi S, Naik G, Hekmatdoost A. Fatty liver index and risk of diabetes incidence: A systematic review and dose-response meta-analysis of cohort studies. Prim Care Diabetes 2020;14:577-83. [PMID: 32694004 DOI: 10.1016/j.pcd.2020.02.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 56 |
Long SQ, Yu XF, Ge YL, Liu LX. Ginkgolide B ameliorates high-fat diet-induced hepatic steatosis and inflammation in mice. Shijie Huaren Xiaohua Zazhi 2020; 28(13): 519-525 [DOI: 10.11569/wcjd.v28.i13.519] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 57 |
Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 58 |
Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol 2020;19:359-66. [PMID: 32349939 DOI: 10.1016/j.aohep.2020.03.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 59 |
Decker RD, Ghiraldi EM, Weiss AH, Gaughan JP, Friedlander JI. Nonalcoholic Fatty Liver Disease Is an Independent Risk Factor for Nephrolithiasis in Women: Findings from NHANES III. J Endourol 2020;34:1258-62. [PMID: 32571100 DOI: 10.1089/end.2020.0486] [Reference Citation Analysis]
|
| 60 |
Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Med Chem 2019;11:2171-92. [PMID: 31538528 DOI: 10.4155/fmc-2019-0003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 61 |
Dey P, Olmstead BD, Sasaki GY, Vodovotz Y, Yu Z, Bruno RS. Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota. J Nutr Biochem 2020;84:108455. [PMID: 32688217 DOI: 10.1016/j.jnutbio.2020.108455] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 62 |
Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, Xin YN. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis 2020;19:118. [PMID: 32475354 DOI: 10.1186/s12944-020-01288-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 63 |
Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, Tatsumi F, Hirukawa H, Sanada J, Kohara K, Irie S, Kimura T, Nakamura Y, Nishioka M, Obata A, Nakanishi S, Mune T, Kaku K, Kaneto H. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.J Diabetes Investig. 2020;11:1612-1622. [PMID: 32329963 DOI: 10.1111/jdi.13279] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 64 |
Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 65 |
Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Reference Citation Analysis]
|
| 66 |
Xu Y, Jiang Y, Li Y. Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k/Akt inhibition. Toxicol Res (Camb) 2020;9:149-57. [PMID: 32670546 DOI: 10.1093/toxres/tfaa015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 67 |
Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 16.7] [Reference Citation Analysis]
|
| 68 |
Yu LY, Li WY, Lin J. Juglanin improves lipid metabolism disorder, liver injury, and intestinal integrity in nonalcoholic fatty liver mice. Shijie Huaren Xiaohua Zazhi 2020; 28(4): 113-121 [DOI: 10.11569/wcjd.v28.i4.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 69 |
Cherkashchenko NA, Livzan MA, Krolevets TS. Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease. Terapevticheskii arkhiv 2020;92:48-54. [DOI: 10.26442/00403660.2020.02.000550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 70 |
Suliman HM, Osman B, Abdoon IH, Saad AM, Khalid H. Ameliorative activity of Adansonia digitata fruit on high sugar/high fat diet-simulated Metabolic Syndrome model in male Wistar rats. Biomed Pharmacother 2020;125:109968. [PMID: 32066041 DOI: 10.1016/j.biopha.2020.109968] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 71 |
Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 72 |
Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, Xin Y. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10. [PMID: 31937252 DOI: 10.1186/s12876-020-1165-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 73 |
Rikhi R, Singh T, Modaresi Esfeh J. Work up of fatty liver by primary care physicians, review. Ann Med Surg (Lond) 2020;50:41-8. [PMID: 31993196 DOI: 10.1016/j.amsu.2020.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 74 |
Romantsova TR, Sych YP. Immunometabolism and metainflammation in obesity. Obes metabol 2019;16:3-17. [DOI: 10.14341/omet12218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 75 |
Gushcha S, Dragomiretska N, Zabolotna I, Nasibullin B, Izha A, Вadiuk N, Koieva K. Possibilities of using natural mineral waters in the treatment of patients with non-alcoholic fatty liver disease. BALNEO 2019;10:450-456. [DOI: 10.12680/balneo.2019.280] [Reference Citation Analysis]
|
| 76 |
Zhao Z, Zhong L, Li P, He K, Qiu C, Zhao L, Gong J. Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. Exp Cell Res 2020;387:111738. [PMID: 31759057 DOI: 10.1016/j.yexcr.2019.111738] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 77 |
Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM, Martínez-Doménech Á, García-Legaz-Martínez M, Alonso-Carpio M, Tamarit-García JJ, Diago-Madrid M, Sánchez-Carazo JL, Pérez-Ferriols A. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: A cross-sectional cohort study. Australas J Dermatol 2020;61:105-9. [PMID: 31731325 DOI: 10.1111/ajd.13175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 78 |
Rinaldi L, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Dig Dis Sci 2019;64:3013-9. [PMID: 30937719 DOI: 10.1007/s10620-019-05604-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 79 |
Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 80 |
Van de Velde F, Bekaert M, Geerts A, Hoorens A, Batens AH, Shadid S, Ouwens M, Van Nieuwenhove Y, Lapauw B. Insulin resistance associates with hepatic lobular inflammation in subjects with obesity. Endocr Connect 2019;8:1294-301. [PMID: 31470414 DOI: 10.1530/EC-19-0366] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 81 |
Grigorescu E, Floria M, Lăcătușu CM, Mircea-mihai B, Creţu I, Popa AD, Onofriescu A, Jaba IM, Șorodoc V, Ceasovschih A, Șorodoc L. The Relationship between Hepatic Steatosis, inflammation and insulin Resistance in type 2 Diabetes with Metabolic Imbalance. Internal Medicine 2019;16:13-25. [DOI: 10.2478/inmed-2019-0073] [Reference Citation Analysis]
|
| 82 |
Barbalata T, Deleanu M, Carnuta MG, Niculescu LS, Raileanu M, Sima AV, Stancu CS. Hyperlipidemia Determines Dysfunctional HDL Production and Impedes Cholesterol Efflux in the Small Intestine: Alleviation by Ginger Extract. Mol Nutr Food Res 2019;63:e1900029. [PMID: 31295384 DOI: 10.1002/mnfr.201900029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 83 |
Romero-Pérez D, Belinchón-Romero I, Bellot P, Francés R, Marco F, Ramos-Rincón JM. Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk. Australas J Dermatol 2019;60:e304-10. [PMID: 31236937 DOI: 10.1111/ajd.13098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 84 |
Ruiz-Tovar J, Zubiaga L. Validation of biochemical scores for liver steatosis before and 1 year after sleeve gastrectomy. Surg Obes Relat Dis 2019;15:1447-53. [PMID: 31204247 DOI: 10.1016/j.soard.2019.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 85 |
Zhang M, Li L, Chen J, Li B, Zhan Y, Zhang C. Presence of diabetic retinopathy is lower in type 2 diabetic patients with non-alcoholic fatty liver disease. Medicine (Baltimore) 2019;98:e15362. [PMID: 31045779 DOI: 10.1097/MD.0000000000015362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 86 |
Nascimbeni F, Pellegrini E, Lugari S, Mondelli A, Bursi S, Onfiani G, Carubbi F, Lonardo A. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. Atherosclerosis 2019;284:66-74. [DOI: 10.1016/j.atherosclerosis.2019.02.028] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 87 |
Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 88 |
Golabi P, Paik J, Reddy R, Bugianesi E, Trimble G, Younossi ZM. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol. 2019;19:56. [PMID: 30991959 DOI: 10.1186/s12876-019-0972-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 89 |
Meng Y, Liu Y, Fang N, Guo Y. Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. Pharm Biol 2019;57:98-104. [PMID: 30757944 DOI: 10.1080/13880209.2019.1568509] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 90 |
Puttabyatappa M, Martin JD, Andriessen V, Stevenson M, Zeng L, Pennathur S, Padmanabhan V. Developmental programming: Changes in mediators of insulin sensitivity in prenatal bisphenol A-treated female sheep. Reprod Toxicol 2019;85:110-22. [PMID: 30853570 DOI: 10.1016/j.reprotox.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 91 |
Katsiki N, Doumas M, Athyros V. Metabolic syndrome: joint diagnostic criteria and links with comorbidities. Hormones (Athens) 2019;18:107-8. [PMID: 30368688 DOI: 10.1007/s42000-018-0074-9] [Reference Citation Analysis]
|
| 92 |
Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 93 |
Zheng F, Cai Y. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet. Lipids Health Dis 2019;18:6. [PMID: 30611282 DOI: 10.1186/s12944-018-0933-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 94 |
Bellan M, Colletta C, Barbaglia MN, Salmi L, Clerici R, Mallela VR, Castello LM, Saglietti G, Carnevale Schianca GP, Minisini R, Pirisi M. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. Diabetes Metab J 2019;43:700-10. [PMID: 31694082 DOI: 10.4093/dmj.2018.0201] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 95 |
Cadegiani FA. The Liver Before and After Bariatric Surgery. Dietary Interventions in Liver Disease 2019. [DOI: 10.1016/b978-0-12-814466-4.00004-5] [Reference Citation Analysis]
|
| 96 |
Iizuka K. The Role of Carbohydrate Response Element–Binding Protein in the Development of Liver Diseases. Dietary Interventions in Liver Disease 2019. [DOI: 10.1016/b978-0-12-814466-4.00022-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 97 |
Qin G, Ma J, Huang Q, Yin H, Han J, Li M, Deng Y, Wang B, Hassan W, Shang J. Isoquercetin Improves Hepatic Lipid Accumulation by Activating AMPK Pathway and Suppressing TGF-β Signaling on an HFD-Induced Nonalcoholic Fatty Liver Disease Rat Model. Int J Mol Sci 2018;19:E4126. [PMID: 30572631 DOI: 10.3390/ijms19124126] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 98 |
Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol 2019;12:256-68. [PMID: 30439626 DOI: 10.1016/j.tranon.2018.10.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 99 |
Li J, Wang S, Yao L, Ma P, Chen Z, Han TL, Yuan C, Zhang J, Jiang L, Liu L, Ke D, Li C, Yamahara J, Li Y, Wang J. 6-gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2019;362:125-135. [PMID: 30408433 DOI: 10.1016/j.taap.2018.11.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 100 |
Lugari S, Mantovani A, Nascimbeni F, Lonardo A. Hypothyroidism and nonalcoholic fatty liver disease - a chance association? Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30367792 DOI: 10.1515/hmbci-2018-0047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 101 |
Domínguez-Pérez M, Simoni-Nieves A, Rosales P, Nuño-Lámbarri N, Rosas-Lemus M, Souza V, Miranda RU, Bucio L, Uribe Carvajal S, Marquardt JU, Seo D, Gomez-Quiroz LE, Gutiérrez-Ruiz MC. Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis. J Cell Physiol 2019;234:7213-23. [PMID: 30239004 DOI: 10.1002/jcp.27474] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 102 |
Albhaisi S, Issa D, Alkhouri N. Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. Hepatobiliary Surg Nutr 2018;7:389-91. [PMID: 30498715 DOI: 10.21037/hbsn.2018.07.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 103 |
Rinaldi L, Folliero V, Palomba L, Zannella C, Isticato R, Di Francia R, Berretta M, de Sio I, Adinolfi LE, Morelli G, Lastoria S, Altucci L, Pedone C, Galdiero M, Franci G. Sonoporation by microbubbles as gene therapy approach against liver cancer. Oncotarget 2018;9:32182-90. [PMID: 30181808 DOI: 10.18632/oncotarget.25875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 104 |
Zampino R, Marrone A, Rinaldi L, Guerrera B, Nevola R, Boemio A, Iuliano N, Giordano M, Passariello N, Sasso FC. Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. Infection. 2018;. [PMID: 30066228 DOI: 10.1007/s15010-018-1185-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 105 |
Skubic C, Drakulić Ž, Rozman D. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opin Drug Metab Toxicol 2018;14:831-41. [PMID: 29969922 DOI: 10.1080/17425255.2018.1492552] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 106 |
Umehara T. Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults. PLoS One 2018;13:e0197900. [PMID: 29897928 DOI: 10.1371/journal.pone.0197900] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 107 |
Bellentani S, Bedogni G, Tiribelli C. Two drinks per day does not take your fatty liver away. Hepatology 2018;67:2072-3. [PMID: 29266329 DOI: 10.1002/hep.29753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 108 |
Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 66] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 109 |
Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 110 |
Patel PJ, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Brown NN, Saad N, Valery PC, Irvine KM, Clouston AD, Stuart KA, Russell AW, Powell EE. Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. J Diabetes Complications 2018;32:799-804. [PMID: 29861312 DOI: 10.1016/j.jdiacomp.2018.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Karlas T. Diagnose und Verlaufsbeurteilung von Fettlebererkrankungen: Relevanz sonographischer Verfahren. Gastroenterologe 2018;13:272-83. [DOI: 10.1007/s11377-018-0263-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 112 |
Adinolfi LE, Marrone A, Rinaldi L. Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. Hepatobiliary Surg Nutr 2018;7:143-6. [PMID: 29744347 DOI: 10.21037/hbsn.2018.02.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 113 |
Chen Q, Liu M, Yu H, Li J, Wang S, Zhang Y, Qiu F, Wang T. Scutellaria baicalensis regulates FFA metabolism to ameliorate NAFLD through the AMPK-mediated SREBP signaling pathway. J Nat Med 2018;72:655-66. [DOI: 10.1007/s11418-018-1199-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 114 |
Zang S, Chen J, Song Y, Bai L, Chen J, Chi X, He F, Sheng H, Wang J, Xie S, Xie W, Yang Y, Zhang J, Zheng M, Zou Z, Wang B, Shi J; Chinese NAFLD Clinical Research Network (CNAFLD CRN). Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. Adv Ther 2018;35:218-31. [PMID: 29411270 DOI: 10.1007/s12325-018-0670-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
